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The ubiquitin-proteasome system (UPS) has been implicated in neurodegenerative
diseases based on the presence of deposits consisting of ubiquitylated proteins in
affected neurons. It has been postulated that aggregation-prone proteins associated with
these disorders, such as α-synuclein, β-amyloid peptide, and polyglutamine proteins,
compromise UPS function, and delay the degradation of other proteasome substrates.
Many of these substrates play important regulatory roles in signaling, cell cycle
progression, or apoptosis, and their inadvertent stabilization due to an overloaded
and improperly functioning UPS may thus be responsible for cellular demise in
neurodegeneration. Over the past decade, numerous studies have addressed the UPS
dysfunction hypothesis using various model systems and techniques that differ in their
readout and sensitivity. While an inhibitory effect of some disease proteins on the UPS
has been demonstrated, increasing evidence attests that the UPS remains operative in
many disease models, which opens new possibilities for treatment. In this review, we
will discuss the paradigm shift that repositioned the UPS from being a prime suspect in
the pathophysiology of neurodegeneration to an attractive therapeutic target that can be
harnessed to accelerate the clearance of disease-linked proteins.
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INTRODUCTION
Proteinopathies form a large group of pathologies that are charac-
terized by the presence of abnormally folded proteins in affected
cells (Carrell and Lomas, 1997). Among those diseases are hered-
itary neurodegenerative disorders, such as Huntington’s disease
(HD), spinal and bulbar muscular atrophy (SBMA), and sev-
eral forms of autosomal dominant spinocerebellar ataxias (SCAs;
types 1-3, 6, 7, 17), caused by polyglutamine (polyQ) repeat
expansions in unrelated proteins (Orr and Zoghbi, 2007; La
Spada and Taylor, 2010). The observation that the expanded
polyQ repeat renders proteins prone to aggregation has raised the
idea that members of this disease family may share a common
pathogenic mechanism (Scherzinger et al., 1997). It has further
been suggested that related pathogenic events may be an under-
lying cause in other neurodegenerative diseases characterized by
the presence of protein aggregates, such as Alzheimer’s disease
(AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis
(ALS) (Sherman and Goldberg, 2001). The technical advantage
of working with monogenic polyQ diseases has brought together
scientists from a broad variety of research disciplines who have
studied the effects of the pathogenic proteins on a wide spectrum
of cellular processes in cultured cells and animal models.
Since the discovery of repeat expansions as a genetic basis
of hereditary neurodegenerative diseases more than two decades
ago (La Spada et al., 1991), we have learned that polyQ proteins
have an impact on diverse cellular processes such as transcrip-
tion, transport, neuronal function, and viability. The long list
of cellular functions affected by these proteins suggests that the
disease-linked proteins disturb one or more systems central to
these processes, causing many downstream pathways to collapse
during the course of pathology. The ubiquitin-proteasome system
(UPS) has received particular attention in the study of neu-
rodegenerative disorders due to its role as a critical regulator
of protein homeostasis in eukaryotic cells. It keeps the cellular
environment free of misfolded, defective, and aggregation-prone
proteins, which have been found to accumulate in neurodegen-
erative diseases (Ciechanover and Brundin, 2003). The protein
quality control function of the UPS is, however, only one of the
essential processes that engages this multitasking proteolytic sys-
tem which governs also cell cycle progression and induction of
apoptosis (Hershko and Ciechanover, 1998). It has been proposed
that the vast amounts of aggregation-prone polyQ proteins may
overwhelm the UPS and compromise other essential functions
of the machinery required for maintaining cellular homeostasis
(Mayer et al., 1989). According to this model, blockade of the UPS
by the disease protein would result in global accumulation of pro-
teasome substrates and thus provides an explanation for the broad
and diverse effects on cellular homeostasis in affected cells.
Many laboratories have addressed the UPS dysfunction
hypothesis over the last decade and it has become evident that
UPS activity is preserved in the majority of neurodegenera-
tive disorders. In the course of these studies, adaptive cellular
responses have been identified that help to alleviate the bur-
den of aggregation-prone proteins to keep ubiquitin-dependent
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proteolysis operative. Here we will discuss the transition of our
view on the UPS from a dysfunctional system that catalyzes cyto-
toxicity in neurodegenerative diseases to a powerful proteolytic
system that may be exploitable in therapeutic strategies aimed at
clearing aggregation-prone proteins from cells.
THE UBIQUITIN-PROTEASOME SYSTEM AS PRIME SUSPECT
The UPS, which is the principal pathway for the clearance of
short-lived, damaged, and misfolded proteins in the nucleus and
cytoplasm, consists of two separate, consecutive steps: ubiquity-
lation and proteasomal degradation (Hershko and Ciechanover,
1998; Kleiger and Mayor, 2014). An enzymatic cascade composed
of ubiquitin activator, conjugase, and ligase catalyzes the covalent
attachment of ubiquitin to a substrate protein. Ubiquitin is con-
jugated via its carboxy-terminal glycine to an internal lysine (Lys)
residue or, less commonly, to the free amino (N) terminus of the
substrate (Pickart, 2001). Multiple rounds of ubiquitylation lead
to the formation of a polyubiquitin chain, which can function
as a signal for degradation by the proteasome, a multi-protein
complex consisting of a 20S core particle and 19S regulatory par-
ticles, at one or both ends. The active sites responsible for the
chymotrypsin-like, trypsin-like, and caspase-like activities of the
proteasome are situated in the interior surface of the 20S core par-
ticle, thereby shielding their proteolytic activities from the rest
of the cellular proteome (Bedford et al., 2010). The proteasome
unfolds substrates and threads the polypeptide chains through
the inner channel, where they are cleaved into short peptides
(Bhattacharyya et al., 2014). Following their release from the bar-
rel, peptides are rapidly processed into amino acids by cellular
aminopeptidases and recycled (Reits et al., 2003).
Ubiquitylation has many other roles in cells besides protea-
somal degradation (Figure 1). The destiny of a given substrate
protein is determined by the type of ubiquitin assembly to
which it is connected. This is possible because ubiquitin con-
tains seven Lys residues in its amino acid sequence at positions
6, 11, 27, 29, 33, 48, and 63, which can serve as acceptors for
additional ubiquitin monomers in the construction of polyu-
biquitin chains (Komander and Rape, 2012). As a result, many
different chain topologies can be formed, which are recognized by
specific ubiquitin-binding adaptors in the relevant cellular path-
ways. Chain topology and substrate specificity are determined by
a large spectrum of ubiquitin-ligating and -modifying enzymes,
whose expression levels and activities are tightly regulated in a
tissue-, cell-, and compartment-specific manner. Several different
types of polyubiquitin linkages target substrates to the protea-
some, such as Lys11 and Lys29 in addition to the canonical
Lys48-linked chains, as well as conjugation of a single ubiqui-
tin molecule (Kravtsova-Ivantsiv and Ciechanover, 2012). Mono-
and polyubiquitin chains also regulate non-proteolytic functions
in cells, such as protein activity and localization (Seet et al., 2006).
While most ubiquitin chains can target proteins for proteaso-
mal degradation, it has been shown that Lys63-linked ubiquitin
chains are the only modification that do not behave as a pro-
teasome targeting signal in vivo (Nathan et al., 2013). Instead
these chains play pivotal roles in signaling, endocytosis, and DNA
repair. More recently, this chain topology has been implicated
in macroautophagy (Kraft et al., 2010), a pathway that targets
FIGURE 1 | Structure and function of common ubiquitin modifications.
Ubiquitin may be conjugated to protein substrates as either a monomer or a
polymeric chain, in which one of seven internal lysine (Lys) residues of
ubiquitin, or the N-terminal methionine, serves as an acceptor for additional
ubiquitin moieties. The type of polyubiquitin linkage dictates the topology of
the resulting chain. Ubiquitin modifications can regulate protein function or
act as a signal in many cellular processes. Examples for functions of
monoubiquitylation, and homogenous Lys11-, Lys48-, and Lys63-linked
polyubiquitin chains are shown.
cytoplasmic proteins and organelles for degradation in lysosomes
(Nakatogawa et al., 2009). Therefore, the UPS is highly inter-
connected with other proteolytic and non-proteolytic cellular
processes at multiple levels, whereby it controls many diverse
functions in cells.
Given the vast amount of proteins that are involved in the
UPS, it is perhaps not surprising that some of them have been
genetically linked to neurodegenerative disorders (Ciechanover
and Brundin, 2003). On first sight, the finding that mutations
in genes encoding components of the UPS can cause or predis-
pose for neurodegeneration supports the notion of inefficient
ubiquitin-dependent proteolysis as a shared pathogenic mecha-
nism. However, it should not be overlooked that the UPS and,
in particular, the ubiquitin-targeting step are connected to many
different processes besides proteasomal degradation. Several cases
of neurodegeneration-linked mutations in UPS components are
now known to affect ubiquitin-dependent processes that do not
target proteins to the proteasome, while the UPS remains largely
operative.
One of the best-studied examples of a UPS component that
has been linked to neurodegeneration is the ubiquitin ligase
Parkin, mutations in which cause an autosomal recessive juvenile-
onset PD (Kitada et al., 1998). Early studies revealed that Parkin
can target endoplasmic reticulum (ER)-derived proteins (Yang
et al., 2003) and polyQ proteins for proteasomal degradation
(Tsai et al., 2003) suggesting that a defect in the UPS-mediated
protein quality control may be responsible for this pathology.
However, during recent years it has become apparent that Parkin
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is also involved in the autophagy pathway that results in the
degradation of dysfunctional mitochondria in lysosomes, a pro-
cess known as mitophagy (Ashrafi and Schwarz, 2013). Parkin
cooperates with the mitochondrial kinase PINK1, which has also
been linked to PD, thus strengthening the genetic association
between mitophagy and neurodegeneration (Clark et al., 2006;
Park et al., 2006). Another theory suggests that Lys63-linked
polyubiquitin chains generated by Parkin may be important for
targeting aggregation-prone proteins to inclusions bodies (IBs)
(Olzmann et al., 2007). Although the possibility remains that UPS
dysfunction contributes to PD, recent studies point to autophagy-
related processes as central to the pathology caused by Parkin
mutations.
Another example is ubiquilin, a ubiquitin-binding shuttle
factor that is involved in escorting polyubiquitylated proteins
to the proteasome for degradation (Elsasser and Finley, 2005).
Overexpression of ubiquilin has a neuroprotective effect in mice
expressing a fragment of the polyQ protein causative for HD,
huntingtin (El Ayadi et al., 2012). A single nucleotide polymor-
phism (SNP) that causes alternative splicing of the ubiquilin
transcript predisposes for late-onset AD (Bertram et al., 2005).
Given the function of ubiquilin as a shuttling substrate recep-
tor in the UPS, it is tempting to speculate that the SNP in
ubiquilin alters the ability of cells to recognize and destroy mis-
folded proteins. However, the AD-linked ubiquilin variants do
not cause a general block of the UPS, but instead, were found to
selectively cause accumulation of presenilin-1, which is involved
in amyloid precursor protein (APP) processing (Viswanathan
et al., 2011). Moreover, ubiquilin-1 functions as a molecu-
lar chaperone that regulates trafficking and processing of APP,
which has been linked to its ability to stimulate polyubiquity-
lation of APP with non-proteolytic Lys63-linked polyubiquitin
chains (El Ayadi et al., 2012). Together this suggests that while
ubiquilin-1 may regulate the production of β-amyloid peptide
at multiple levels in a ubiquitin-dependent fashion, the variants
linked to AD do not seem to trigger a general failure of the
UPS.
The ubiquitin-selective chaperone valosin-containing pro-
tein (VCP) has also attracted attention from researchers who
study the link between the UPS and neurodegenerative disor-
ders. Mutations in VCP cause multisystem proteinopathy (MSP),
with among its spectrum of symptoms frontotemporal demen-
tia (Watts et al., 2004), as well as the motor neuron disease
amyotrophic lateral sclerosis (ALS) (Johnson et al., 2010). VCP
is critical for proteasomal degradation of certain proteins and
it is believed that it does so by means of its ATP-dependent
chaperone activity that can unfold or segregate proteasome sub-
strates from their environment (Stolz et al., 2011). However,
ubiquitin-dependent functions of VCP are not limited to pro-
teasomal degradation (Dantuma and Hoppe, 2012; Meyer et al.,
2012) and include ubiquitin-selective autophagy (Ju et al., 2009;
Tresse et al., 2010), the clearance of stress granules (Buchan et al.,
2013), mitochondrial integrity (Bartolome et al., 2013), Parkin-
dependent mitophagy (Kim et al., 2013), and the DNA damage
response (Acs et al., 2011; Meerang et al., 2011). Overexpression
of VCP mutants linked to MSP and ALS did not inhibit the UPS
(Tresse et al., 2010), whereas some of the VCP-mediated events
mentioned above were altered (Ju et al., 2009; Tresse et al., 2010;
Bartolome et al., 2013; Fujita et al., 2013; Kim et al., 2013), sug-
gesting that the pathology caused by mutant VCP likely involves
essential ubiquitin-dependent processes that are different from
proteasomal degradation.
A unique example of a protein responsible for a polyQ neu-
rodegenerative disease that is involved in ubiquitin-dependent
proteasomal degradation is ataxin-3. It functions as a deubiqui-
tylation enzyme that reverses the ubiquitin mark on proteins by
disassembling Lys48- and Lys63-linked polyubiquitin chains with
a preference for the latter (Winborn et al., 2008). Expansion of
the polyQ repeat that resides in ataxin-3 are the underlying cause
for the most common form of autosomal dominant SCA, known
as SCA-3 or Machado-Joseph disease. Notably, ataxin-3 physi-
cally interacts with VCP and regulates proteasomal degradation
of ER-derived substrates (Wang et al., 2006; Zhong and Pittman,
2006). Overexpression of either wild-type or polyQ-expanded
ataxin-3 compromises the functionality of the UPS resulting in
increased levels of proteasome substrates (Burnett et al., 2003).
Interestingly, non-expanded ataxin-3 is also a known suppressor
of polyQ toxicity in models of SCA-3 and other polyQ diseases
(Warrick et al., 2005). Although the reason for this protective
effect is poorly understood, it may be attributed to the ability of
ataxin-3 to stimulate sequestration ofmisfolded proteins (Burnett
and Pittman, 2005). Finally, ataxin-3 regulates the ubiquityla-
tion status of Parkin and stimulates its degradation by autophagy,
linking also this protein to other ubiquitin-dependent systems
(Durcan et al., 2011). This study, like the previous examples, sug-
gests a complex relationship between the UPS and neurodegener-
ation and shows that the effects of disease-associated proteins on
ubiquitin-dependent proteolysis are difficult to predict.
Two important lessons can be drawn from the afore-
mentioned examples. First, each one of these examples under-
scores the prevalent notion that the UPS is tightly connected
to neurodegenerative disorders. The fact that unrelated diseases
share the presence of causative mutations in UPS components
leaves little doubt that the UPS plays a central role in these
pathologies. Second, they illustrate that care should be taken
when extrapolating genetic data to disease mechanisms. Thus,
the general view that a compromised UPS is responsible for the
typical accumulation of misfolded proteins in neurodegenerative
diseases is problematic due the complex and multilayered con-
nection between the UPS and a variety of cellular functions. The
fact that a large number of essential cellular functions other than
protein quality control require ubiquitin conjugation or protea-
somal degradation leaves the possibility open that the role of the
UPS in these pathologies may be largely unrelated to ubiquitin-
dependent protein quality control. A definite answer on whether,
and if so, to what extent, impairment of the UPS contributes
to the development of neurodegenerative diseases can only be
obtained by empirically assessing the functional status of the UPS
in each of these diseases.
UBIQUITIN-POSITIVE INCLUSIONS
A hallmark of neurodegenerative diseases is the accumulation
of abnormal proteins in insoluble deposists, or IBs. The idea
that impaired clearance of misfolded proteins may be central to
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neurodegenerative diseases originates in part from the observa-
tion that IBs contain ubiquitin, proteasome subunits, and other
UPS components (Cummings et al., 1998). Mori et al. who
first described the presence of ubiquitin in IBs, already spec-
ulated that either the protease responsible for degrading ubiq-
uitylated proteins (which was not known at that time to be
the proteasome) was dysfunctional, or that ubiquitylated pro-
teins residing in the inclusions resisted degradation (Mori et al.,
1987).
For a long time, the nature of IBs has been under debate
(Sisodia, 1998). While some researchers argued that they were
innocent bystanders, others favored the view that IBs were directly
implicated in the cellular pathology caused by aggregation-prone
proteins (Sherman and Goldberg, 2001). One hypothesis that has
appeared in different forms with various key players suggests that
physical entrapment of proteins in IBs removes functional pro-
teins from critical cellular processes. With respect to the UPS and
chaperones, one can picture how sequestration may compromise
their household function and elicit cellular pathology. According
to yet another model, IBs are part of the cellular defense mech-
anism that protects cells against toxicity by functioning as a sink
for misfolded proteins. A wealth of data in support for the lat-
ter option comes from cell biologists who found that ectopic
overexpression of abnormal proteins triggers a sequence of reac-
tions that results in the deposition of the misfolded proteins
into specific perinuclear structures, which were coined aggre-
somes (Wojcik et al., 1996; Johnston et al., 1998; Garcia-Mata
et al., 1999). These findings argue against the view that IBs are
formed by passive aggregation, but instead require active, ATP-
dependent processes in cells (Kopito, 2000). Moreover, related
protein deposits have been documented in budding yeast, which
suggests that this cellular response is conserved throughout evo-
lution and serves cytoprotective functions in both unicellular and
multicellular eukaryotic organisms (Kaganovich et al., 2008). In
dividing cells, IBs are distributed asymmetrically to daughter cells
during mitosis ensuring the generation of healthy progeny devoid
of proteineous deposits (Rujano et al., 2006).
The most compelling evidence supporting a role of IBs as an
adaptive response comes from live cell recordings, which show
that IB formation correlates with increased survival in primary
neurons expressing a mutant huntingtin fragment (Arrasate et al.,
2004). This is consistent with the finding that reducing the load
of IBs, achieved by genetically inhibiting ubiquitylation, enhances
polyQ-mediated neurodegeneration in a SCA-1 mouse model
(Cummings et al., 1999). Inclusions are reversible and highly
dynamic structures, as switching off expression of a mutant hun-
tingtin fragment (Yamamoto et al., 2000) or mutant ataxin-1 (Zu
et al., 2004) in conditional mouse models results in the clearance
of ubiquitin-positive IBs. When it comes to the UPS components
and chaperones associated with IBs, it has been demonstrated
that these factors do not appear to be physically trapped in IBs
(Kim et al., 2002; Stenoien et al., 2002; Holmberg et al., 2004).
A recent study even suggests that proteasomes play an active
role inmaintaining or dissolving these structures (Schipper-Krom
et al., 2014). Furthermore, POH1/Rpn11, a proteasome subunit
with deubiquitylation activity, stimulates the formation of IBs by
generating free ubiquitin chains in proximity of the aggregated
proteins and results in the recruitment of HDAC6 (Hao et al.,
2013), which orchestrates ubiquitin-dependent transport of pro-
teins to the aggresome (Kawaguchi et al., 2003). Altogether, these
findings support a protective function of IBs in cells facing large
amounts of misfolded proteins. Increasing evidence suggests that
IBs may act as a hub for misfolded and aggregated proteins and
redirect them to alternative destruction mechanisms, which will
be discussed later.
PROTEASOME ACTIVITY IN NEURODEGENERATIVE
DISEASES
One possibility to get a better insight into the functionality
of the UPS is by assessing the individual enzymatic activi-
ties involved in ubiquitin-dependent proteasomal degradation
(Lindsten and Dantuma, 2003). Ubiquitylation, on one hand,
is the net result of a large family of enzymes that are involved
in proteolytic and non-proteolytic processes and are therefore
not straight-forward to address or to interpret. The proteasome,
on the other hand, is the final destination of all ubiquitylated
substrates to be degraded and creates a bottleneck in the UPS
pathway. Its function is readily traceable to the individual pro-
teolytic subunits whose activities can be measured by using
specific fluorogenic substrates (Kisselev and Goldberg, 2005) or
activity probes (Verdoes et al., 2006). It is therefore not sur-
prising that the proteasome has received a lot of attention in
studies that assess the functionality of the UPS in neurode-
generative diseases. However, correlation of proteasome activity
measurements and UPS impairment in neurodegenerative dis-
eases is complicated by the fact that it is presently unknown to
what extent altered proteasome activity affects the overall flux of
degradation of ubiquitylated substrates. Fibroblasts derived from
mice with a heterozygous deletion of PSMC1/Rpt2, one of the
ATPase subunits of the 19S regulatory particle, develop without
obvious defects despite reduced proteasome function (Rezvani
et al., 2012). Moreover, proteasome activity can be regulated
through expression of individual subunits. For example, increas-
ing the amount of active proteasomes, either through overexpres-
sion of the 20S core component PSMB5/β5 responsible for the
chymotrypsin-like activity or the proteasome assembly chaperone
hUMP1/POMP, improves resistance to oxidative stress insults in
human fibroblasts (Chondrogianni et al., 2005; Chondrogianni
and Gonos, 2007). Likewise, levels of the PSMD11/Rpn6 pro-
teasome subunit, which stabilizes the interaction between the
regulatory and core particle and facilitates ubiquitin-dependent
degradation (Pathare et al., 2012), can regulate proteasome activ-
ity (Vilchez et al., 2012a,b).
Translating how certain levels of proteasome inhibition will
jeopardize the functional status of ubiquitin-dependent protea-
somal degradation poses another unresolved problem in assessing
the status of the UPS through proteasome activity measurements.
Experiments with yeast strains expressing mutant proteasome
subunits suggest that the proteolytic sites are non-redundant and
vary in their contribution to overall protein degradation (Rubin
et al., 1998). The chymotrypsin-like activity of the proteasome
needs to be reduced by more than 80 percent in human cells
before the clearance of ubiquitylated proteins becomes notice-
ably delayed (Dantuma et al., 2000; Bence et al., 2001). Even when
Frontiers in Molecular Neuroscience www.frontiersin.org July 2014 | Volume 7 | Article 70 | 4
Dantuma and Bott The UPS in neurodegenerative diseases
this threshold is not reached, a lower degree of inhibition of the
chymotrypsin-like activity does, however, impair the cells’ ability
to deal with an acute increase in the flux of ubiquitylated proteins
during stress conditions (Dantuma et al., 2000). In mammalian
cells, individual proteasome activities also differ in their contribu-
tion to overall protein degradation since the caspase-like activity
can be chemically ablated without affecting the ability of cells to
clear ubiquitylated proteins (Myung et al., 2001). Therefore, the
differential contribution of individual proteolytic activities, the
high level of redundant proteasome activity, and indirect effects
of the stress status, which determine the load of ubiquitylated
substrates, complicate the interpretation of proteasome activity
measurements when it comes to the functional status of the UPS.
Initial studies have measured proteasome activity in post-
mortem human tissues and reported decreased activity in neu-
rodegenerative disorders (Table 1). However, follow-up experi-
ments with purified proteasomes, cell lines, and animal models
have not always been consistent with those early reports. While in
some studies a decrease in proteasome activity has been reported,
others have found that the activity is unchanged or even increased
(for references see Table 1). Increased proteasome activity could
be an adaptive response to the augmented load of misfolded
proteins in these diseases but there are also alternative explana-
tions. In this respect, it is important to point out there is a set of
alternative proteolytic subunits that can replace the constitutive
proteases in the proteasome in response to interferon γ (Kniepert
and Groettrup, 2014). The resulting immunoproteasome plays
an important role in generating peptide fragments for antigen
display by major histocompatibility complex class I proteins on
the cell surface. Thus, changes in the activity of the proteasome
may also be attributed to induction of immunoproteasomes in
inflammatory response, which are commonly observed in neu-
rodegenerative diseases (Czirr and Wyss-Coray, 2012). Indeed
induction of immunoproteasome subunits have been reported
in mouse models of polyQ disorders (Diaz-Hernandez et al.,
2003) and other neurodegenerative diseases (Mishto et al., 2006;
Cheroni et al., 2009; Orre et al., 2013).
An exceptional case, in which the presence of an aggregation-
protein has been mechanistically linked to inhibition of the
proteasome, is the prion protein, which causes when misfolded
the fatal, transmissible neurodegenerative disorder Creutzfeld-
Jacob disease. Wild-type prion proteins residing in the cytosolic
compartment of cells are efficiently degraded in a ubiquitin-
dependent fashion (Yedidia et al., 2001) whereas cytosolic mutant
prion proteins form aggresomes, which is accompanied by signs
of apoptotic cell death (Kristiansen et al., 2005). It has been shown
that oligomers of mutant prion protein effectively inhibit the
activity of the proteasome in vitro and in vivo (Kristiansen et al.,
2007) through direct binding of oligomers to the 20S proteasome
core particle, which results in stabilization of a closed confirma-
tion of the proteasome (Deriziotis et al., 2011). As a consequence,
prion protein inhibits proteolysis by preventing substrate access
to the proteasome core.
The main constituent of the Lewy bodies in PD, α-synuclein,
has also been shown to bind to proteasomes (Snyder et al., 2003)
and inhibit UPS function in vitro and in vivo (Stefanis et al.,
2001; Snyder et al., 2003; Chen et al., 2006). Cytoplasmic amyloid
β peptide can also interact with the proteasome (Gregori et al.,
1995), however, its effect on proteasome activity is debated (for
references see Table 1). Moreover, it is not clear if proteasome
inhibition by α-synuclein or β-amyloid is mechanistically related
to that of prion proteins.
For polyQ proteins, it has been shown that ubiquitylated fil-
amentous aggregates of mutant huntingtin isolated from mouse
or human brain samples can selectively inhibit the proteolytic
activity of the proteasome (Diaz-Hernandez et al., 2006). We
will discuss below that several studies suggest that this inhibitory
activity of huntingtin aggregates does not compromise the UPS
in vivo (Bett et al., 2009; Maynard et al., 2009; Ortega et al., 2010).
Moreover, mutant huntingtin fragments have not been found to
inhibit degradation of ubiquitylated substrates by the 26S protea-
some in vitro (Hipp et al., 2012). Whether or not polyQ proteins
can be degraded by the mammalian proteasome has been the sub-
ject of a considerable debate (Venkatraman et al., 2004; Pratt and
Rechsteiner, 2008; Juenemann et al., 2013). Puromycin-sensitive
aminopeptidase has been identified as the main cytosolic protease
to efficiently clear expanded polyQ peptides generated by the pro-
teasome in vitro (Bhutani et al., 2007). It has been hypothesized
that proteasome-derived polyQ fragments may enhance aggre-
gate formation (Venkatraman et al., 2004; Raspe et al., 2009),
but it is unclear whether these species are actually generated
in vivo. In cultured cells, aggregation of mutant huntingtin frag-
ment is exacerbated following treatment with the proteasome
inhibitor lactacystin (Waelter et al., 2001). Moreover, enhancing
UPS-mediated clearance of polyQ proteins reduces their levels
and toxicity, suggesting that the net outcome of accelerated pro-
teasomal degradation is beneficial in polyQ diseases (Verhoef
et al., 2002; Michalik and Van Broeckhoven, 2004).
FUNCTIONAL STATUS OF THE UPS IN NEURODEGENERATIVE
DISEASES
UPS functionality, which describes the relative rate at which
cells ubiquitylate and degrade proteins at a given time, can be
addressed in cells and tissues in several ways. These approaches
are based on the assumption that cells that cannotmaintain a con-
stant flux through the UPS will gradually build up ubiquitylated
proteasome substrates irrespective of their nature. As explained
earlier, the relationship between UPS activity and levels of sub-
strates is often complex. Reduced proteasome activity does not
necessarily lead to functional impairment of the UPS as long
as the activity is sufficient to process ubiquitylated proteins tar-
geted for destruction. Vice versa, ubiquitin-dependent proteolysis
in cells can be severely impaired despite the presence of a nor-
mal proteasome activity profile. Furthermore, cells may mobilize
compensatory mechanisms to assist a suboptimal but functioning
UPS.
A straight-forward approach to assess UPS activity in cells
or tissues measures the abundance or quality of ubiquitylated
proteins. However, ubiquitylation is involved in many cellular
processes other than proteasomal degradation (Komander and
Rape, 2012) and it is therefore difficult to extrapolate whether a
possible build up in ubiquitylated proteins is a consequence of
UPS impairment or reflects other changes in the ubiquitin home-
ostasis (Groothuis et al., 2006). Substrate flux through the UPS
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Table 1 | Overview of measurements of the proteolytic activity of the proteasome in neurodegenerative disease models.
Disease Protein context Model system Reduced activity? References
Polyglutamine
disease
Polyglutamine GFP
fusion
COS-1 cell line No Michalik and Van Broeckhoven, 2004
SHSY5Y cell line No Ding et al., 2002
Htt fragment Purified proteasomes Yes/Noa Diaz-Hernandez et al., 2006
No Bennett et al., 2005; Hipp et al., 2012
Neuro2a cell line Yes Jana et al., 2001
ST14A cell line Yes Seo et al., 2007
R6/2 mice No Bett et al., 2006; Wang et al., 2008;
Maynard et al., 2009
HD94 mice No Diaz-Hernandez et al., 2003
Ataxin-7 Sca7266Q/5Q mice No Bowman et al., 2005
Androgen receptor AR97Q mice No Tokui et al., 2009
HD postmortem brain; patient fibroblasts Yes Seo et al., 2004
Polyalanine
disease
PABPN1 OPMD A17.1 mice No Trollet et al., 2010
Alzheimer’s
disease
β-amyloid peptide Purified proteasomes Yes Gregori et al., 1995; Tseng et al., 2008
No Kristiansen et al., 2007
B103 cell line Yes Song et al., 2003
GT1 and N2aPK-1 cell lines; cerebellar
granule neurons
No Kristiansen et al., 2007
Primary astrocytes and neurons Yes Lopez Salon et al., 2003
Neuro2a and N9 cell lines; primary
astrocytes and microglia
No Orre et al., 2013
Tg2576 mice Yes Oh et al., 2005; Almeida et al., 2006
3xTg-AD mice Yes/Nob Tseng et al., 2008
APP/PS1 mice Yes/Noc Aso et al., 2012
No Orre et al., 2013
AD postmortem brain Yes Keller et al., 2000; Lopez Salon et al.,
2000; Keck et al., 2003; Mishto et al., 2006
No Orre et al., 2013
Parkinson’s
disease
Wild type
α-synuclein
Purified proteasomes Yes Snyder et al., 2003
HEK293 and BE-M17 cell lines Yes Snyder et al., 2003
hwα-SYN-5 mice Yes Chen et al., 2006
Mutant
α-synuclein
PC12 cell line Yes Stefanis et al., 2001; Tanaka et al., 2001
hm2α-SYN-39 mice Yes Chen et al., 2006
Parkin Parkin loss-of-function flies;
Parkin null-mice
Yes Um et al., 2010
LRRK2 HeLa cell line No Lichtenberg et al., 2011
PD postmortem brain Yes McNaught and Jenner, 2001; McNaught
et al., 2003
ALS Mutant SOD1 Purified proteasomes No Kristiansen et al., 2007
Neuro2A cell line Yes Urushitani et al., 2002
NT-2, SK-N-MC, and SH-SY5Y cell lines No Lee et al., 2001; Casciati et al., 2002;
Aquilano et al., 2003
GT1 and N2aPK-1 cell lines; cerebellar
granule neurons
No Kristiansen et al., 2007
ALS/IBMPFD VCP Purified proteasomes Yes Gitcho et al., 2009
Retinal
degeneration
Transducin
γ-subunit
G−/−
γ1 mice No Lobanova et al., 2013
Prion disease Prion protein Purified proteasomes Yes Kristiansen et al., 2007; Deriziotis et al.,
2011
GT1 and N2aPK-1 cell lines; cerebellar
granule neurons
Yes Kristiansen et al., 2007
aFilamentous htt but not inclusions isolated from HD94 mice was shown to inhibit the 26S proteasome in vitro without affecting 20S proteasome function.
bDecreased proteasome activity observed only at early time points; no difference compared with wild type at late disease stages.
cDecreased chymotryptic activity, but no decreased tryptic- and caspase-like activity.
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can be assessed by determining the levels or half-lives of cellu-
lar proteins. An important caveat with this approach is that the
degradation of endogenous proteasome substrates is often tightly
regulated and likely to change depending on internal or external
cues. Particularly in the context of neurodegenerative diseases,
altered degradation rates of endogenous substrates likely reflect
functional differences in protein stabilization rather than changes
in overall UPS activity. This problem can be circumvented by
the use of reporter substrates, which have been developed for
monitoring protein degradation by the UPS. These reporters are
typically based on fluorescent proteins fused to degradation sig-
nals that target the fusion protein for constitutive turnover via the
UPS (Neefjes and Dantuma, 2004). They include the ubiquitin-
dependent reporters UbG76V-green fluorescent protein (GFP) and
GFPu that are targeted via an N-terminal ubiquitin or a short CL1
peptide motif, respectively (Dantuma et al., 2000; Bence et al.,
2001). Another commonly used reporter, based on the degron
derived from mouse ornithine decarboxylase (ODC), is degraded
in a ubiquitin-independent fashion (Murakami et al., 1992). UPS
reporter substrates are in principle devoid of intrinsic regulatory
elements to eliminate the impact of variables such as posttransla-
tional modifications, which can affect the half-life of endogenous
protein substrates. Although all these reporter proteins are sub-
ject to degradation by the 26S proteasome, they are recognized
by distinct targeting pathways and therefore differ in sensitiv-
ity and signal-to-background ratio. It has been shown that levels
of the reporters inversely correlate with UPS activity (Dantuma
et al., 2000; Bence et al., 2001). Accumulation of reporter pro-
tein relative to baseline levels is typically interpreted as reduced
UPS function, however, reporter protein levels may be affected by
changes in expression (Bowman et al., 2005; Tokui et al., 2009)
or protein synthesis, to which they are very sensitive as a con-
sequence of their short half-life (Li et al., 1998). These reporter
substrates are important tools for studying UPS functionality in
cell and mouse models of neurodegenerative diseases (Table 2).
In cell culture experiments, an N-terminal fragment of polyQ-
expanded huntingtin has been shown to impair the degradation
of the endogenous substrate p53 (Jana et al., 2001) and GFPu
(Bence et al., 2001). UPS inhibition appears to be a consequence
of protein aggregation and not a unique feature of polyQ pro-
teins since the unrelated aggregation-prone protein mutant cystic
fibrosis membrane conductance regulator (CFTR) has a similar
effect on the UPS (Bence et al., 2001). GFPu reporter accu-
mulation correlates with induction of apoptosis, supporting a
model in which UPS impairment induced by protein aggrega-
tion proteins is responsible for cell death although it cannot
exclude that other adverse effects are responsible for the cytotox-
icity (Bence et al., 2001). UPS impairment as a result of polyQ
proteins affects both the nuclear and cytosolic UPS and does not
seem to be confined to the compartment that accumulates the
aggregation-prone proteins, arguing for general interference with
UPS function (Bennett et al., 2005). A study utilizing a version
of the GFPu reporter targeted to the synapse of neurons sug-
gested that mutant huntingtin primarily affects UPS function in
the synaptic compartment (Wang et al., 2008). It is noteworthy
that later studies found the artificial CL1 degradation signal in
GFPu to render proteins aggregation-prone (Menendez-Benito
et al., 2005; Link et al., 2006), which is not surprising if one
considers that this artificial degradation signal mimics targeting
signals present in ER-derived proteasome substrates (Gilon et al.,
2000). Subsequent studies have shown that the polyQ huntingtin
fragment also affects the degradation of other UPS reporters,
such as UbG76V-GFP, signifying that this effect is not limited to
aggregation-prone proteins (Maynard et al., 2009; Mitra et al.,
2009; Hipp et al., 2012). Analysis in a cellular model demonstrates
that aggregates of N-terminal huntingtin do not directly impair
the proteasome, instead, the increase in ubiquitylated proteins
likely reflects a general disturbance of the cellular proteostasis
network (Hipp et al., 2012).
Two transgenic mouse models expressing GFP-based reporter
substrates for the UPS, UbG76V-GFP (Lindsten et al., 2003) and
GFPu (Bove et al., 2006), have been instrumental in addressing
UPS functionality in neurodegeneration in vivo. Using thesemice,
it has been demonstrated that UPS function is preserved in ani-
mals expressing polyQ-expanded proteins such as the N-terminal
huntingtin fragment, R6/2 (Bett et al., 2009; Maynard et al.,
2009; Ortega et al., 2010), androgen receptor (AR) responsible
for SBMA (Tokui et al., 2009), and ataxin-7 that causes SCA-7
(Bowman et al., 2005). The lack of UPS impairment in the R6/2
mouse model has been particularly puzzling since the evidence
for a globally dysfunctional UPS in cultured cells has largely been
based on ectopic expression of the very same huntingtin fragment
that is expressed in these mice (Bence et al., 2001; Jana et al., 2001;
Bennett et al., 2007; Wang et al., 2008).
The development of quantitative mass spectrometry combined
with efficient purification of ubiquitylated proteins or signa-
ture peptides from biological samples has been invaluable in
undertaking detailed analysis of the ubiquitylated proteome in
human diseases (Kessler, 2013). This method not only allows
the determination of total ubiquitin levels, but also enables dis-
crimination of different types of ubiquitin chains. Quantitative
mass spectrometry has been successfully applied to investigate
the composition of ubiquitin conjugates in R6/2 mice and HD
patient brain and revealed accumulation of Lys11-, Lys48-, and
Lys63-linked ubiquitin chains (Bennett et al., 2007). In theory,
the increase in Lys11- and Lys48-linked ubiquitin chains would
be consistent with a functional blockade of the UPS as both chain
topologies can target proteins to the proteasome (Komander and
Rape, 2012). However, Lys63-linked polyubiquitin chains also
accumulate in HD and are not normally associated with pro-
teasomal degradation (Nathan et al., 2013), suggesting that the
effect of polyQ-expanded huntingtin on ubiquitin homeostasis
is more complex than simple blockade of the UPS. In support
of this view, two independent studies have not detected stabi-
lization of UbG76V-GFP (Maynard et al., 2009) or GFPu (Bett
et al., 2006) in R6/2 mice. Ubiquitin conjugates observed in R6/2
brains have also been shown to differ qualitatively from those
observed upon proteasome inhibition (Maynard et al., 2009),
indicating that the observed increase in ubiquitylation in HDmay
be due to changes in ubiquitin-dependent processes other than
proteasomal degradation.
While data obtained with mouse models for polyQ dis-
eases have unequivocally supported the presence of a pre-
served UPS, UPS impairment has been detected in models of
Frontiers in Molecular Neuroscience www.frontiersin.org July 2014 | Volume 7 | Article 70 | 7
Dantuma and Bott The UPS in neurodegenerative diseases
Table 2 | Overview of measurements of the functionality of the ubiquitin/proteasome system in neurodegenerative disease models.
Disease Protein context Model system Readout Reduced References
function?
Polyglutamine
disease
Htt fragment Yeast Ub-R/P-lacZ; CPY*-HA Yes Duennwald and Lindquist,
2008
HEK293 cell line GFPu Yes Bence et al., 2001
NES/NLS-GFPu Yes Bennett et al., 2005
UbG76V-GFP; Ub-R-GFP;
GFP-CL1; ODC-GFP;
GFP-dF508CFTR; TCRalpha-GFP
Yes Hipp et al., 2012
PC12 cell line Ub-R/P-GFP; CD3delta-HA Yes Duennwald and Lindquist,
2008
UbG76V-YFP; YFP-CL1 Yes Maynard et al., 2009
R6/2 mice GFPu No Bett et al., 2009
UbG76V-GFP No Maynard et al., 2009
HD94 mice UbG76V-GFP Yesa Ortega et al., 2010
Ataxin-1 HEK293T cell line d2EGFP (ODC) Yes Park et al., 2005
HEK293 cell line NES/NLS-GFPu Yes Bennett et al., 2005
Ataxin-7 Sca7266Q/5Q mice UbG76V-GFP No Bowman et al., 2005
Androgen receptor HEK293 cell line GFPu Yesb Mandrusiak et al., 2003
NSC34 cell line YFPu, NES/NLS-YFPu Yesc Rusmini et al., 2007
AR121Q flies GFPu Yesb Pandey et al., 2007
AR97Q mice UbG76V-GFP No Tokui et al., 2009
Alzheimer’s
disease
β-amyloid peptide B103 cell line GFPu Yes Song et al., 2003; Oh et al.,
2005
HEK293 cell line ZsProsensor (ODC) Yes Tseng et al., 2008
Ubiquilin-1 HEK293T cell line UbG76V-YFP No Viswanathan et al., 2011
APPswePS1dE9 mice UbG76V-GFP No Orre et al., 2013
GFPu Yes Liu et al., 2014a
Parkinson’s
disease
α-synuclein Yeast GFPu Yes Outeiro and Lindquist, 2003
LRRK2 HeLa cell line UbG76V-GFP Yes Lichtenberg et al., 2011
ALS SOD1 NSC34 cell line YFPu Yes Crippa et al., 2010; Onesto
et al., 2011
NES/NLS-YFPu No Sau et al., 2007
C2C12 cell line YFPu No Onesto et al., 2011
SOD1G93A mice UbG76V-GFP Yesd Cheroni et al., 2009
ALS/IBMPFD VCP U2OS cell line dF508CFTR Yes Weihl et al., 2006
Meljuso cell line UbG76V-GFP;
CD3delta-GFP
No Tresse et al., 2010
Retinal
degeneration
Rhodopsin mutant HEK293 cell line GFPu Yes Illing et al., 2002
NES/NLS-GFPu Yes Bennett et al., 2005
P23H, Rho−/−, andRds mice UbG76V-GFP Yes Lobanova et al., 2013
Transducin
γ-subunit
G−/−
γ1 mice Ub
G76V-GFP Yes Lobanova et al., 2013
Prion disease Prion protein N2aPK-1 cell line UbG76V-GFP Yes Kristiansen et al., 2007
Prion-infected mice UbG76V-GFP Yes Kristiansen et al., 2007
aTransient UPS impairment.
bUPS impairment by mutant AR is ligand-dependent.
cUPS impairment by mutant AR occurs only in absence of ligand; ligand treatment restored UPS functionality.
dReduced UPS activity observed only at late stages in cells which display advanced ALS pathology (e.g., enlarged vacuoles).
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other neurodegenerative diseases. For example studies with the
UbG76V-GFP reporter mice have shown that UPS impairment
occurs during progression in an ALS mouse model expressing
mutant SOD1 (Cheroni et al., 2009). Likewise, UPS impairment
has been demonstrated in a mouse model of prion pathology,
which is consistent with a role for direct UPS impairment by the
prion protein (Kristiansen et al., 2007). Opposing findings have
been reported in the well-characterized APPswe/PS1dE9 mouse
model for AD. A recent study has demonstrated accumulation of
GFPu reporter as well as the endogenous proteasome substrate
p53 in this model (Liu et al., 2014a), whereas the same mouse
model did not accumulate UbG76V-GFP according to another
report (Orre et al., 2013). Although documented for some dis-
orders, global inhibition of ubiquitin-dependent proteolysis does
not appear to be a universal feature of neurodegenerative diseases.
COMPENSATORY MECHANISMS
The absence of functional impairment of the UPS in mouse mod-
els of polyQ diseases does not imply that the UPS is unaffected
by the presence of aggregation-prone proteins. In cellular mod-
els, polyQ proteins have been shown to elicit UPS inhibition,
indicating that they can have a general negative impact on intra-
cellular proteolysis. Transgene expression levels are an important
difference between the cell lines and mouse models. In cells, pro-
teins are typically transiently overexpressed in an acute manner
whereas proteins are expressed chronically at modest levels in
transgenic mice, more similar to the situation in human patients.
The effect of acute induction of the N-terminal mutant hun-
tingtin fragment has been addressed in vivo (Ortega et al., 2010)
using a mouse model in which huntingtin expression can be reg-
ulated by administration of doxycyclin (Yamamoto et al., 2000).
Interestingly, acute overexpression of the mutant huntingtin frag-
ment in these mice is accompanied by increased levels of the
UbG76V-GFP reporter substrate in neuronal and non-neuronal
cells. Importantly, accumulation of the UPS reporter is of a tran-
sient nature, suggesting that cells activate adaptive responses to
restore UPS activity (Ortega et al., 2010). Restoration of UPS
function coincides with IB formation in neurons (Mitra et al.,
2009; Ortega et al., 2010), which is consistent with a protec-
tive role of inclusions through sequestration of toxic oligomeric
species. In support of this model, the UbG76V-GFP reporter has
been shown to accumulate also in R6/2 mice following treatment
with chemical inhibitors of protein aggregation, which block the
formation of IBs (Heiser et al., 2002; Ortega et al., 2010).
The autophagy pathway is tightly connected with the UPS
and can play a compensatory role in maintaining intracellular
protein degradation under conditions of reduced UPS activity.
Autophagy counteracts the toxicity of mutant huntingtin, pos-
sibly through promoting the removal of aggregated, oligomeric
species (Ravikumar et al., 2004). Moreover, autophagy induc-
tion reversed UPS impairment in a Drosophila model of SBMA
(Pandey et al., 2007). Chemicals that inhibit lysosomal degra-
dation also compromise the UPS, suggesting that autophagy is
required for proper functioning of ubiquitin-dependent protea-
somal degradation (Korolchuk et al., 2009). Autophagy likely
assists the UPS in the removal of a pool of problematic protea-
some substrates, such as aggregated or damaged proteins, which
would otherwise impede UPS activity. It has been suggested that,
analogous to UPS dysfunction in neurodegeneration, autophagy
may be compromised in polyQ diseases (Ravikumar et al., 2004).
Interestingly, experiments in mice have shown that autophagy
dysfunction results in a neurodegeneration phenotype associated
with ubiquitin-positive inclusions, indicating that an impaired
autophagolysosomal system can recapitulate neurodegeneration
(Hara et al., 2006; Komatsu et al., 2006).
Ubiquitin, which serves a wide range of cellular functions
besides proteasomal degradation, is closely involved in these com-
pensatory mechanisms (Figure 2). It has been shown to target
proteins to aggresomes by a mechanism that involves HDAC6,
a cytosolic deacteylation enzyme that binds unanchored ubiqui-
tin chains and facilitates the sequestration of aggregated proteins
in IBs (Kawaguchi et al., 2003). The ability of specific adap-
tor proteins, such as p62 and NBR1, to simultaneously bind
polyubiquitylated cargo and the autophagosome marker LC3 also
supports a central role for ubiquitin in selective autophagy (Kraft
et al., 2010). However, the role of ubiquitin as a decisive signal in
autophagy has been questioned and instead it has been argued
that protein oligomerization and not ubiquitylation is the pri-
mary signal (Riley et al., 2010). Both the formation of aggresomes
(Olzmann et al., 2007) and ubiquitin-selective autophagy (Tan
et al., 2008) are typically associated with Lys63-linked ubiquitin
chains, although the involvement of other chain topologies is less
clear. Notably, monoubiquitin can suffice as a signal to direct pro-
teins to the autophagosome (Kim et al., 2008). More experiments
are needed to dissect the functions of ubiquitin and the relative
contribution of individual chain topologies in cellular processes.
The fact that ubiquitin is shared between targeting mecha-
nisms that direct substrates to the proteolytic machinery and
adaptive responses, which counteract toxic proteins, suggests
a functional significance in directing the joint efforts of these
pathways in eliminating harmful proteins (Groothuis et al., 2006).
FIGURE 2 | Cellular pathways that counteract protein aggregation are
ubiquitin-dependent processes. Proteins linked to neurodegenerative
diseases, such as α-synuclein, β-amyloid peptide and polyQ proteins, are
prone to misfolding and aggregation in the cellular environment. The
proteasome, autophagy, and inclusion bodies form a network of quality
control systems which reduces levels of misfolded proteins and
counteracts aggregation. All three pathways are regulated by ubiquitylation.
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It is possible that the accumulation of polyubiquitin conjugates
in polyQ diseases may be due to upregulation of ubiquitin-
dependent adaptive responses, such as the formation of inclusions
or activation of ubiquitin-selective autophagy, which through
their actions may preserve UPS activity. Thus, rather than being
a consequence of a functional impaired UPS, the accumula-
tion of ubiquitin conjugates may be part of the reason why
the UPS remains operative even in the challenging intracellular
environment of polyQ disease.
REDUCING LEVELS OF NEURODEGENERATION-ASSOCIATED
PROTEINS
In monogenic, dominant neurodegenerative disorders in which
the identity of the disease-causing mutant proteins is known, as
in the case of the polyQ disorders, an obvious but technically
less trivial therapeutic approach would be to reduce the levels of
the mutant protein. However, some of the gene products fulfill
important functions in cells and may even be essential for via-
bility, as is the case for huntingtin (Dragatsis et al., 2000) and
ataxin-7 (Helmlinger et al., 2004). This problem may be circum-
vented by designing strategies to selectively target the mutated
protein without affecting the wild-type form. Additionally, exper-
iments in inducible mouse models for HD (Yamamoto et al.,
2000) and SCA-1 (Zu et al., 2004) have shown that switch-
ing off expression of polyQ proteins reverses disease symptoms
and neuronal pathology. A recent study has demonstrated that
decreasing expression of polyQ-expanded ataxin-7 by 50 percent
results in a full phenotypic rescue in a conditional SCA-7 mouse
model (Furrer et al., 2013), which suggests that modest reduc-
tion of polyQ proteins may suffice for therapeutic intervention
in humans. Targeting expression of mutant transcripts using
RNA interference or antisense oligonucleotide technology is a
promising approach to achieve this goal (Bonini and La Spada,
2005).
An alternative strategy for reducing levels of disease proteins
is to accelerate their turnover by the UPS, whose function is
preserved even at late stages of pathology. However, the ques-
tion remains whether or not the proteasome can efficiently
degrade disease-linked proteins. Some studies have suggested
that the proteasome cannot degrade the polyQ proteins (Dyer
and McMurray, 2001; Jana et al., 2001; Holmberg et al., 2004;
Venkatraman et al., 2004) whereas others other reports show that
they can be efficiently degraded by the proteasome as long as
they remain in a soluble state (Verhoef et al., 2002; Kaytor et al.,
2004; Michalik and Van Broeckhoven, 2004; Juenemann et al.,
2013; Tsvetkov et al., 2013). Also, α-synuclein, expression levels
of which can predispose individuals to PD (Singleton et al., 2003),
can be degraded by the proteasome (Bennett et al., 1999), suggest-
ing that other aggregation-prone proteins can be targeted by the
UPS.
Several studies show that stimulating ubiquitylation and
degradation of disease proteins through the UPS can rescue
pathology in cell and animal models. For example, increas-
ing the pool of free ubiquitin through genetic overexpression
suppresses α-synuclein-induced neurodegeneration inDrosophila
(Lee et al., 2009). The phenotypic rescue depends on the ability
of the transgenic ubiquitin to form Lys48-linked polyubiquitin
chains that typically target proteins for proteasomal degradation.
Overexpression of certain ubiquitin ligases, which determine sub-
strate specificity in the UPS pathway, also can confer protection
in neurodegeneration models. Increasing levels of the ubiquitin
ligase CHIP (C terminus of Hsc-70 interacting protein) delays the
disease phenotype in SCA-1 (Al-Ramahi et al., 2006) and SBMA
animal models (Adachi et al., 2007) through enhanced ubiqui-
tylation and subsequent clearance of polyQ-expanded proteins.
Moreover, Parkin has been shown to ubiquitylate ataxin-3 and
reduces polyQ toxicity in cells (Tsai et al., 2003; Morishima et al.,
2008). These findings show that the UPS is a plastic and versa-
tile system that can be harnessed to accelerate the clearance of
disease-linked proteins.
LEVERAGING PROTEASOMAL DEGRADATION
Augmenting UPS activity or targeting its activity toward disease-
associated proteinsmay be achieved through small molecules and,
though challenging, opens up the possibility of counteracting
protein accumulation in neurodegeneration (Figure 3). One such
strategy takes advantage of the fact that aggregation-prone pro-
teins are better substrates for the UPS in their monomeric, soluble
state compared to oligomeric assemblies. Compounds, which
stimulate expression or activity of heat shock proteins, effectively
counteract aggregation and increase the clearance of misfolded
proteins through the UPS. The compound arimoclomol induces
chaperone expression and has been shown to ameliorate disease
in SBMA (Malik et al., 2013) and ALS mice (Kalmar et al., 2012).
YM-1, a small molecule that increases the ability of the molecular
chaperone Hsp70 to bind unfolded substrates, increases degrada-
tion of polyQ-expanded AR in cell culture and rescues toxicity in
SBMA flies (Wang et al., 2013).
Stimulation of UPS activity is another means by which degra-
dation of disease protein can be achieved. An important question
is whether such a complex system involving a large number of
proteins can be effectively activated by small molecules in a thera-
peutic setting. Recent studies have revealed that the capacity of
the UPS can be regulated via two related transcription factors,
Nrf1 and Nrf2. Nrf1 is synthesized as an ER-anchored protein
and only becomes transcriptionally active in the nucleus when
increased UPS function is required (Radhakrishnan et al., 2010;
Grimberg et al., 2011). Nrf2 regulates the antioxidant response
in cells and can stimulate expression of proteasome subunits,
which likely increases degradation of oxidized proteins during
stress (Pickering et al., 2012). Nrf2 can be induced by the small
molecule sulforaphane, which increases proteasome levels and
activity (Kwak et al., 2003, 2007), and enhances UPS function
in vivo (Liu et al., 2014b). Sulforaphane has been shown to
reduce mutant huntingtin protein and mitigate polyQ toxicity in
neuronal cells (Liu et al., 2014b).
Ubiquitin-dependent proteasomal degradation of
aggregation-prone proteins can also be stimulated through
direct modulation of proteasome function (Lee et al., 2010).
The regulatory particle of the proteasome harbors two deu-
biquitylation enzymes, namely UCH-L5 and USP14/Ubp6,
that counteract proteasomal degradation by trimming ubiq-
uitin chains of recruited substrates (Finley, 2009). It is has
been proposed that chain trimming by proteasome-associated
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FIGURE 3 | Targeting the ubiquitin-proteasome system (UPS) in
neurodegenerative disorders using small molecules or engineering
approaches. Various events in the UPS can be targeted by
compounds in order to stimulate UPS activity. Among those events
are accelerating of ubiquitylation by compounds or engineered
ubiquitin ligases, inhibition of deubiquitylation, inhibition of protein
aggregation so that the proteins remain in a state that is
permissible to proteasomal degradation and stimulation of the
formation of inclusion bodies which may reduce the load of
aggregation-prone proteins and preserve UPS activity.
deubiquitylation enzymes may function as a molecular timer
that determines the time window during which the proteasome
can initiate degradation, thereby rescuing poorly ubiquitylated
proteins from degradation (Lam et al., 1997). IU1, a selective
small molecule inhibitor of USP14, has been shown to accelerate
proteasomal degradation of aggregation-prone proteins, includ-
ing proteins associated with neurodegenerative diseases such as
tau, TDP43 and the polyQ protein ataxin-3, as well as oxidized
proteins (Lee et al., 2010). However, it remains to be seen whether
IU1 is effective in mitigating disease manifestations in animal
models of neurodegenerative disorders.
SELECTIVE PROTEASOMAL TARGETING OF DISEASE
PROTEINS
Increasing overall degradation by stimulating UPS activity may be
accompanied by unwanted side effects due to their general nature.
Selectively targeting the disease-causing proteins for proteaso-
mal is therefore expected to have many advantages over general
stimulation of UPS activity. The specificity of the UPS action
towards disease-linked proteins can be increased by taking advan-
tage of the natural regulatory systems that dictate the degradation
rates of these proteins. While this method has the potential of
reducing side-effects of increasing overall UPS activity, it requires
detailed insights in the biological function and regulation of the
disease-causing protein.
Among the proteins implicated in polyQ diseases, AR is prob-
ably the one whose functions are best understood. AR is a nuclear
hormone receptor that is linked to various types of cancers,
most notoriously prostate cancer (Matsumoto et al., 2013). The
idea of using small molecule inhibitors of heat shock protein 90
(Hsp90) as therapeutic tools in SBMA originates from cancer
studies which revealed that AR is an Hsp90 client and requires
heat shock proteins for proper functioning (Prescott and Coetzee,
2006). It has been shown that geldanamycin analogs 17-AAG
and 17-DMAG accelerate degradation of AR and other Hsp90
client proteins and reduce polyQ-expanded AR toxicity in cell and
mouse models (Waza et al., 2005; Tokui et al., 2009). Interestingly,
geldanamycin is also effective in preventing aggregation ofmutant
huntingtin, which has been attributed to the ability of Hsp90
inhibitors to induce a general heat shock response (Sittler et al.,
2001). Activation of the heat shock response may also contribute
to lowering of AR half-life by geldanamycin analogs in SBMA
models, as overexpression of heat shock proteins has been shown
to also promote AR degradation (Bailey et al., 2002). Small
molecules that promote the deposition of aggregation-prone pro-
teins into IBsmay also be beneficial in neurodegenerative diseases.
For example, the compound B2 has been shown to increase
inclusion formation of the mutant huntingtin fragment, polyQ-
expanded AR, and α-synuclein, and thereby suppresses toxicity in
cell and fly models (Bodner et al., 2006; Palazzolo et al., 2010).
Protein stability can be influenced by posttranslational mod-
ifications. One example for this is again AR, whose levels and
subcellular localization is controlled by the PI3K-Akt signaling
pathway. It has been shown that phosphorylation of mutant
AR by the Akt kinase, which can be induced by insulin-like
growth factor-1 (IGF-1), accelerates clearance of the receptor
by the proteasome (Palazzolo et al., 2007). Importantly, IGF-1
reduces mutant AR aggregation and toxicity in SBMA models
in vitro and in vivo (Palazzolo et al., 2009; Rinaldi et al., 2012).
More recently, it has been shown that the turnover of ataxin-1 is
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regulated by phosphorylation by MSK1 and, accordingly, the lev-
els of polyQ-expanded ataxin-1 could be reduced by depletion of
MSK1 (Park et al., 2013). The phosphorylation event is controlled
by components in the MAPK-Ras pathway, and pharmacological
curtailing of the MAPK pathway with small compound inhibitors
of MEK1/2 or Raf1 similarly reduced levels and toxicity of mutant
ataxin-1 (Park et al., 2013).
In recent years, scientists have begun to explore the possi-
bility to mobilize branches of the UPS that are not normally
involved in handling aggregation-prone proteins. Earlier stud-
ies have shown that engineered chimeric ubiquitin ligases can
be used to redirect the ubiquitylation machinery to proteins of
interest (Zhou et al., 2000). Engineered ubiquitin ligases typically
contain two domains: a recognition domain specific to the pro-
tein of interest, and a ubiquitylation domain. Examples for the
latter are RING, HECT, and U-box domains, which directly cat-
alyze the addition of ubiquitin to the substrate. Ubiquitylation
domains may also guide the substrate protein to the enzymatic
activity of a ubiquitin ligase, such as the SCF complex via the F
box domain (Zhang and Zhou, 2005). An example of engineered
ubiquitin ligases in the context of neurodegenerative diseases is a
chimeric Dorfin-CHIP fusion that combines the substrate bind-
ing domain of the ubiquitin ligase Dorfin with the U-box of CHIP.
The resulting fusion protein was found to ubiquitylate mutant
SOD1more efficiently than the wild-type Dorfin or CHIP ubiqui-
tin ligases (Ishigaki et al., 2007). Off-target effects due to residual
activity toward their native substrates, or unwanted regulation in
the cellular microenvironment are a major caveat with current
chimeras based on domains derived from endogenous proteins.
However, an important advantage of the chimeras is that they can
be designed with high specificity to certain sub-populations of
the protein-of-interest. For instance, a recent study reported the
generation of an SCF-βTrCP ubiquitin ligase that selectively tar-
gets only activated ErbB receptor tyrosine kinases for degradation
(Kong et al., 2014).
Nanobody-based fusions are variations on protein chimeras
based on single chain antibodies, which, when expressed in the
intracellular environment, bind to target proteins with high speci-
ficity (Muyldermans, 2013). A fusion consisting of an F-box
domain and a nanobody directed to GFP has been successfully
used to deplete cytoplasmic, nuclear, and transmembrane GFP-
fusion proteins in cultured cells and in vivo via the SCF complex
(Caussinus et al., 2012). In theory, this approach may also be used
to engineer intrabody-based ubiquitin ligases specific to disease-
associated proteins, or even to pathogenic protein conformations.
Although engineered ubiquitin ligases can be of great value in
experimental settings and provide us with a proof-of-principle
that ubiquitylation can be tailored to accelerated degradation of
desired proteins, there are currently many practical limitations
that limit their adaptation to therapeutic settings, such as safety
and delivery to target tissues.
A number of studies have explored whether small molecules
can be used to redirect endogenous ubiquitylation enzymes
to defined target substrates. Most interesting in this respect is
the work on molecules known as Protacs (Proteolysis-targeting
chimeric molecules) and SNIPERs (Specific and non-genetic
IAP-dependent Protein Erasers) (Buckley and Crews, 2014). Both
types of molecules combine a ubiquitin ligase interaction pep-
tide with a small molecule ligand specific for the target protein
(Sakamoto et al., 2001). Protacs have mainly been developed to
target cancer-relevant gene products but may be applicable as
well to misfolded proteins in neurological disorders. One exam-
ple is a chimeric molecule that unites a peptide motif fromHIF1α
with the AR ligand dihydrotestosterone (DHT) and can be used
to accelerate degradation of AR in cultured cells (Rodriguez-
Gonzalez et al., 2008). Although it would be interesting to test
whether this molecule can also accelerate the degradation of
mutant AR in SBMA or whether derivatives can be generated
for other polyQ proteins, a limiting factor in the development of
Protacs is poor permeability across cell membranes and potential
antigenicity due to their peptidic nature. However, in the cases
where the ubiquitin ligase can be recruited by small synthetic
molecules instead of polypeptides, it may be possible to obtain
compounds with potential therapeutic value. A functional cell-
permeable Protac combines two active molecules, the AR ligand
DHT and the Mdm2-interacting compound Nutlin, to increase
ubiquitylation of AR by Mdm2 (Schneekloth et al., 2008). In
SNIPERs, an IAP1-interacting bestatin ester replaces the peptide
domain found in Protacs that links the chimericmolecule to ubiq-
uitin ligase activity. SNIPERs have been used successfully in the
context of steroid receptors, including AR, and efficiently reduce
receptor protein levels at lower molar concentrations than Protacs
(Okuhira et al., 2013). Small molecules for targeted degradation
of disease-associated proteins by the UPS have so far mainly been
explored in the cancer field, but the successful application in
malignant cells may serve as a proof-of-principle to warrant their
investigation in neurodegenerative disorders.
CONCLUDING REMARKS
Increasing evidence suggests that ubiquitin-dependent proteoly-
sis is largely operative in many neurodegenerative diseases, and
hence a causal relationship does not exist between aggregation-
prone proteins and global UPS impairment. While perturbations
in UPS function due to disease proteins cannot be excluded,
adaptive responses such as IB formation and autophagy likely
contribute to the restoration of cellular protein homeostasis. This
knowledge justifies further exploration of the protein degradation
machinery for treating or preventing debilitating neurodegenera-
tive disorders. However, in order to fully appreciate the potential
of the UPS as a therapeutic target, we need to continue to deci-
pher how the UPS and compensatory pathways coordinate the
detoxification and clearance of misfolded proteins.
While the current data do not support a scenario in which
global impairment of the protein quality control function of the
UPS lies at the basis of proteinopathies, our present understand-
ing strongly supports an involvement of ubiquitin-dependent
processes in the development or progression of neurodegener-
ative diseases. Dissecting the molecular mechanisms and key
players responsible for changes in ubiquitylation may help to
identify suitable therapeutic targets. Because it appears to be
unlikely that this inhibitory activity is a shared intrinsic feature
of aggregation-prone proteins, it will be important to study the
interplay between the UPS and the individual disease-associated
proteins in the context of their native functions.
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This change of perspective from the UPS as a potential cause
for neurodegeneration to it being a preserved proteolytic path-
way that may be exploited in therapeutic approaches has been an
important contribution of the large number of studies that have
probed into the role of the UPS in polyQ disorders. Inspiring
examples can be found in the identification of compounds
which stimulate UPS activity and the development of small
molecules that target desired proteins for proteasomal degrada-
tion. Although these studies provide us with proofs-of-principle
for redirecting proteins to endogenous ubiquitin ligases, there is
a clear need for compounds with more favorable drug-like prop-
erties in order to accomplish this aim in a physiological setting.
If successful, such small molecules could be used on their own
or in combination with other polyQ protein-reducing therapies,
such as RNA interference, to reduce the levels of the toxic proteins
in patients. Despite the fact that much needs to be done before
we can start to evaluate the applicability of such approaches, the
recent insight that at least the UPS is still on our side in fighting
the toxic effects of the these rogue proteins opens other oppor-
tunities in the pursuit for therapeutics for neurodegenerative
diseases.
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